Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andy Smith

Latest From Andy Smith

Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings

Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.

Stock Watch Companies

Stock Watch: J&J And Roche Invite Comparison

Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?

Stock Watch Sales & Earnings

Stock Watch: Reading The Tea Leaves For Pharma Q1 Earnings

Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.

Stock Watch Sales & Earnings

Stock Watch: The Two Sides Of A Complete Response Letter

The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.

Complete Response Letters Companies

Stock Watch: Unconventional Biosimilar Wisdom

Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run.

Biosimilars Stock Watch

Stock Watch: The Complex Biologics Market Is…Complex

The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.

Stock Watch Biosimilars
See All
UsernamePublicRestriction

Register